Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by Farmer9on Sep 02, 2013 5:32pm

159 Views

Post# 21713544

RE:SAN FRAN SAN FRAN

SanFrancisco99 is getting harder and harder to take. I feel bad so much money has been lost but time to face facts and move on. Only when RVX is delisted will SanFrancisco99 move on. Until then SanFrancisco99 will spin everything possible to try and make a silver lining. Even a delisting will have a silver lining. "RVX has been delisted because the medications are so advanced and effective, they have shouldn't be owned by common people" blah, blah, blah.

Bullboard Posts

Drilling company poised to capitalize on market conditions